News Archives Year: 2019

Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group Meeting

Immusoft To Present At The International Conference On Lymphocyte Engineering 2019

Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer

Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing

Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update

Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)

Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors

Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

selectION, Inc. Announces $4.1M Series A Investment